Comparisons of the effectiveness of chemotherapy and transplantation in AML in first complete remission (CR) have focused almost exclusively on patients with de novo disease. Here we used Cox modelling to compare these strategies in patients with MDS and s-AML treated by the Leukemia Group of the EORTC or at the MD Anderson Cancer Center. All patients were aged 15-60. The 184 EORTC patients received conventional dose ara-C + idarubicin + etoposide for remission induction, and after one consolidation course, were scheduled to receive an allograft, or an autograft if a sibling donor was unavailable. The 215 MDA patients received various high-dose ara-C containing induction regimens, and in CR, continued to receive these regimens at reduced dose for 6-12 months. CR rates were 54% EORTC and 63% MDA (P = 0.09). Sixty-five of the 100 EORTC patients who entered CR received a transplant in first CR. Disease-free survival in patients achieving CR was superior in the EORTC cohort, the 4-years DFS rates were 28.9% (s.e. = 4.8%) EORTC vs 17.3% (s.e. = 3.7%) MDA (P = 0.017). Survival from CR was not significantly different in the EORTC and MDA groups, as was survival from start of treatment. After accounting for prognostic factors the conclusions were unchanged. Despite various problems with the analysis discussed below, the data suggest that neither transplantation nor chemotherapy, as currently practised, can be unequivocally recommended for these patients in first CR and that questions as to the superior modality may be less important than the need to improve results with both.
Introduction
It is established that the prognosis of some patients presenting with myelodysplastic syndromes (MDS) resembles that of patients with AML. Such patients include those classified as having 'intermediate-2' or 'high' risk MDS by the International Prognostic Scoring System (IPSS). 1 These patients typically have RAEB or RAEB-t, or more rarely CMMoL or RA but with particularly severe cytopenias. These observations have led to the use of AML-type therapy in younger patients meeting these criteria. [2] [3] [4] It is similarly well-known, however, that outcome of AMLtype therapy in such patients is poor, and, in particular, is worse than that seen in patients with de novo AML. The poor results in turn raise the question of the value of transplantation in first CR in patients with MDS. Although there have been frequent comparisons between continued chemotherapy and transplantation in this setting in patients with de novo AML, [5] [6] [7] such comparisons are lacking in patients with MDS. Rather, the literature is dominated by reports of one approach or the other, usually as conducted by a single center or a single consortium of centers. [8] [9] [10] [11] [12] [13] [14] [15] The purpose of this paper is to formally compare continued chemotherapy and transplantation in first CR in patients under age 60 years with high-risk MDS or secondary AML (s-AML), recalling that the response to AML-type therapy in the latter is more reminiscent of that seen in MDS than in de novo AML. Patients were treated at the MD Anderson Cancer Center (MDA) or by the Leukemia Group of the European Organization for Research and Treatment of Cancer (EORTC) in cooperation with SAKK, GIMEMA and EBMT (EORTC study 06921). 16 All patients received AML-type therapy in order to achieve a CR. Subsequently, after an intensive consolidation course, patients treated by the EORTC received an allogeneic transplant, or lacking an HLA-matched sibling donor, an autologous transplant. In contrast, patients treated at MD Anderson continued to receive AML-type therapy but without a transplant. Below we report the results of analyses designed to determine, after accounting for important covariates such as age and cytogenetics, which strategy produced superior outcomes in the combined group of 399 patients (184 EORTC, 215 MDA).
Patients and methods
Between November 1992 and March 1997 184 evaluable patients from 35 European centers were entered in the EORTC 06921 study. Two hundred and fifteen comparable patients were treated between January 1990 and December 1997 at MDA. One hundred and thirty-eight of the EORTC patients (75%) had MDS, and 46 secondary AML. One hundred and thirty-one (61%) of the MDA patients had MDS and 84 s-AML. AML and the various subtypes of MDS were defined using FAB criteria. 17, 18 Patients with AML M3 were excluded. The MDA reported 23 patients with more than 30% blasts in the peripheral blood and less than 30% bone marrow blasts. These patients were classified as peripheral acute leukemia. 19 Selection criteria were those used in the EORTC 06921 study. Patients were included if they were aged 15-60 years, had a WHO/Zubrod performance status р2 and had untreated (1) RAEBt, (2) RAEB with more than 10% blasts cells in the bone marrow, (3) other forms of MDS with multiple chromosomal abnormalities and/or profound cytopenias (neutrophil count Ͻ0.5 × 10 9 /l and/or platelet count Ͻ20 × 10 9 /l), or (4)
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CMMoL with Ͼ5% blasts cells in the bone marrow or Ͼ16 × 10 9 /l neutrophils or Ͼ2.6 × 10 9 /l monocytes in the blood. Since MDA used protocols not calling for AML-type therapy to treat CMMoL, MDA patients with CMMoL were not included in the study group. The outcome of CMMoL patients in the EORTC study was not different from that of the RAEBt patients and therefore these patients were not excluded from the analysis. Patients with secondary AML, ie AML supervening after overt MDS or after an antecedent haematological disorder (AHD) of more than 6 months duration or after prior chemotherapy and/or radiotherapy for another, presumably cured, disease were included. Criteria for an AHD included any of the following: hemoglobin Ͻ12 g/dl, platelet count Ͻ150 × 10 9 /l, neutrophil count Ͻ1.5 × 10 9 /l or white blood count (WBC) Ͼ20 × 10 9 /l. Many patients in whom a local physician first documented such abnormalities did not have bone marrow examined until referred to the treating center (EORTC or MDA). Therefore, an AHD was said to be present when the blood count abnormality was first documented regardless of whether a marrow was done simultaneously. Karyotyping was done using standard techniques and criteria. 20 A normal karyotype, minus Y, inv(16) or t(8;21) were considered to convey a better prognosis, abnormalities involving chromosomes 5 and/or 7 a worse prognosis and other abnormalities an intermediate prognosis.
Treatment in EORTC 06921 (Table 1)
Remission-induction in the 06921 study consisted of conventional dose ara-C, idarubicin and etoposide (ICE, Table 1 ). In case of a partial response a second remission-induction course was given. Patients in CR received one consolidation course consisting of ara-C combined with mitoxantrone (NOVIA, Table 1 ). HLA family typing was initiated at the onset of remission-induction therapy, with the intention of allografting patients in first CR after the course of NOVIA if they had a compatible sibling donor. All patients without a donor were scheduled for autologous bone marrow transplantation or peripheral blood stem cell transplantation. In the initial phase of the study autologous bone marrow cells were used. Since the hematological recovery after transplantation was very prolonged, the protocol was adapted and bone marrow stem cells were replaced by peripheral blood stem cells mobilized with filgrastim during the recovery phase of the consolidation Table 1 Treatment schedules (n = number of patients) MDA treatments (Table 1) All remission-induction regimens used at the MD Anderson contained high-dose ara-C alone (n = 5 patients) or combined with (1) anthracycline (n = 146: daunorubicin 15, idarubicin 131), (2) fludarabine (n = 135) with (n = 92) or without (n = 43) idarubicin, or (3) topotecan (n = 21). Growth factors were used in 136 patients during and after chemotherapy (GM-CSF: 15, G-CSF: 121). Once in CR patients received post-remission therapy of similar type but at a lower dose intensity every 5-6 weeks for 6-12 months.
Definitions
CR was defined conventionally. Response in patients not achieving CR was called either 'resistant' or 'early death'. Disease was considered resistant if the post-day 28 marrow showed Ͼ5% blasts in a marrow that was у20% cellular. We did not distinguish between failure to ever meet these criteria and regrowth of disease after meeting them prior to achievement of CR. Disease was also considered resistant if the marrow remained hypoplastic for more than 42 days from the start of treatment, because of the likelihood that had CR been achieved it would have been very transient. 21 Early death was said to have occurred if death occurred before day 28 or between days 28 and 42 in patients in whom the marrow between these dates was Ͻ20% cellular with Ͻ5% blasts.
Statistical analysis
The duration of survival was calculated from the date of start of treatment until death, whatever the cause. For patients who achieved CR after induction, the disease-free survival was calculated from the date of first CR until the date of first relapse or until death in CR. The duration of survival of remitters corresponds to the time from first CR to the date of death. The actuarial curves were computed using the Kaplan-Meier technique. 22 The Cox Proportional Hazards Model and the Wald test have been used to determine the prognostic importance of several factors regarding the time to event outcomes (DFS, survival from CR, overall survival) and to obtain estimates of the hazard ratios and the corresponding 95% confidence intervals (CI). 22 All analyses were performed according to the intent-to-treat principle.
A total of 325 events are required to detect a 10% difference (20% vs 30%) in terms of DFS at 4 years between the two studies (alpha = 5%, beta = 20%). This corresponds to a haz-ard ratio of 0.75. A lower number of events (ie deaths) and a smaller difference in terms of survival from CR, provides a smaller statistical power for the statistical comparison between the outcome of the studies. The linear logistic model 23 has been used to assess the prognostic importance of several factors, including the study (EORTC or MDA), for reaching CR after induction courses. The Wald test has been used to obtain the P value and assess the 95% confidence interval of the odds ratio. The distribution of patient characteristics in the two studies has been compared using the usual chi-square test.
Results

Patients
Patients' characteristics are shown in Table 2 . MDA patients were older and more likely to have a poor performance status and s-AML, while EORTC patients were more likely to have MDS. Sixteen CMMoL patients were included in the EORTC study. The outcome of these patients was similar to the outcome of RAEBt patients, with 4-year survival rates of 29% for CMMoL and 32% for RAEBt, respectively. Excluding CMMoL patients from the analysis would emphasise the imbalance between the percentage RAEBt patients in the MDA (71%) and EORTC (43%) study. Abnormalities of chromosomes 5 and/or 7 denoting particularly poor prognoses were more common at MDA. The hemoglobin level and platelet count at the start of therapy were lower in MDA patients, while the white blood count (WBC) was higher. The median follow-up for EORTC patients was 3.6 years and for MDA patients 3.0 years.
Response rates
CR rates were 54% (100/184) in the EORTC and 63% (135/215) at MDA (P = 0.09). The estimated odds ratio was 0.71 (=(100/84)/(135/80)) with a 95% confidence interval (CI) of 0.47-1.05. Over 85% of the CRs occurred after the first course of treatment. The lower response rate in the EORTC reflected a higher rate of resistance (30% vs 17%), with rates of early death of 16% EORTC and 19% MDA.
Outcome after CR
Thirty-nine of the 100 EORTC patients who achieved a CR had a compatible sibling donor. Twenty-eight of these 39 received an allograft. Thirty-six out of 61 patients without a donor were autografted (19 autologous bone marrow transplantation and 17 peripheral blood stem cell transplantation). One additional patient underwent a matched unrelated donor transplantation in first CR after the consolidation course. Thirty-five patients were not transplanted in first CR. Two patients died due to toxicity of the consolidation course, 26 patients showed an early relapse and seven patients went offstudy due to toxicity or treatment refusal.
The outcome of patients with an HLA-identical donor (scheduled for allogeneic BMT) did not significantly differ from the outcome of patients without an HLA-identical donor (scheduled for autologous stem cell transplantation). The 4-year DFS rates in the group with or without an HLA-identical donor were 31% (s.e. = 7.9%) and 27% (s.e. = 6.1%), respectively. Therefore, for the purpose of this study, we did not discriminate between allogeneic and autologous transplantation Leukemia and considered it as one strategy. DFS from time of CR was longer for the EORTC patients as compared to MDA patients (P = 0.017, Figure 1 ). The median DFS was 1.0 years (EORTC) vs 0.8 years (MDA), the 4-year DFS rate estimates were 28.9% (s.e. = 4.8%) vs 17.3% (s.e. = 3.7%) and the hazard ratio was 0.69 with a 95% confidence interval (CI) of 0.50-0.95. Among EORTC patients who achieved CR, 32% remained alive in first CR, 52% had disease recurrence and 16% died in first CR.
The corresponding figures at MDA were 20%, 72% and 8%. 
Survival
Survival from CR was not statistically different (P = 0.29) between the EORTC and MDA patients (Figure 2 ). The median survival from CR was 1.5 vs 1.4 years, the 4-year survival from CR rate estimates were 34.4% (s.e. = 5.1%) vs 25.5% (s.e. = 4.6%), the estimated hazard ratio was 0.84 with a 95% CI of 0.61-1. 16 .
Survival from the start of treatment was also similar in EORTC and MDA (Figure 3) . The median survival was 1.08 vs 0.95 years, the 4-year survival estimates were 26.0% (s.e. = 3.5%) vs 18.4% (s.e. = 3.2%), the estimated hazard ratio was 0.85 with a 95% CI of 0.61-1.20.
Prognostic factors: univariate analyses
The following variables appeared to be prognostic factors for overall survival considering all 399 patients: cytogenetics (four categories: good, intermediate, bad prognostic, not done/insufficient metaphases), age as a continuous variable, platelet count as a categorial variable (Ͻ50, 50-99, у100 × 10 9 /l), WBC as a continuous variable, hemoglobin as a categorial variable (Hb Ͻ10 g/dl vs у10 g/dl) and performance status (WHO/Zubrod 0,1 vs 2).
Figure 2
Survival of 235 patients from complete remission by study (100 EORTC, 135 MDA). N, number of patients; O, number of deaths. Important prognostic factors for disease-free survival were cytogenetics, hemoglobin and disease category (RA, RARS, RAEB vs RAEBt, CMMoL vs sAML).
Multivariate analyses
The question remained whether the different outcomes in the EORTC and MDA cohorts (higher CR rate at MDA vs superior DFS, although comparable survival, once in CR in the EORTC) reflected the different treatment regimens (ICE/NOVIA and then transplant in CR by the EORTC vs higher doses of ara-C in induction, continued chemotherapy without transplant in CR at the MDA) or, rather differences in the patients treated (eg a greater frequency of −5/−7 at MDA). We addressed this question by examining which factors ('covariates') independently predicted the various outcomes (CR, DFS in CR, survival in CR, survival). We considered the following covariates: treatment site (EORTC or MDA), and the ones which appeared of prognostic importance in univariate analyses (cytogenetics, disease category, WBC, age, platelet count, haemoglobin and performance status).
A linear logistic regression model showed ( Table 3 ) that treatment site (EORTC or MDA) remained important for achievement of CR.
The Cox's model indicated ( Table 4 ) that after accounting for relevant covariates, treatment in the EORTC was associa- Table 3 Results of linear logistic model for predicting the CR a Baseline category for cytogenetic risk group comprised all patients without good cytogenetic features, for platelets was Ͻ50 × 10 9 /l, for study was MDA. b A value Ͼ1 indicates that the chances of reaching CR are higher for that category in comparison with the baseline. /l, for hemoglobin was Ͻ10 g/dl, for study was MDA. White blood count (WBC × 10 9 /l) and age (years) were considered as continuous varables. b A value Ͻ1 indicates that the outcome is better for that category in comparison with the baseline.
ted with longer DFS, while survival in CR and overall survival were not significantly influenced by treatment site.
Discussion
The relative merits of chemotherapy vs transplantation once patients with AML achieve CR have been debated for years. The discussion has focused primarily on patients with de novo AML given that patients with MDS or s-AML have often been ineligible for AML trials. Recently, however, the possibility of including such patients in protocols examining AML-type therapy has gained attention, and hence questions about the relative benefits of various treatments for such patients have arisen. These questions prompted this paper, which we believe is the first to address the comparative benefits of chemotherapy and transplantation in MDS and s-AML, recalling that these disease entities are more closely linked to each other than to de novo AML.
In our study multivariate analyses revealed several independent prognostic factors for outcome. For disease-free survival not only a treatment including transplantation, but also the absence of cytogenetic abnormalities and a hemoglobin level of at least 10 g/dl predicted for a better outcome. Since most institutions handle a cut-off value of 10 g/dl or less for a blood transfusion this value designates patients who are transfusion independent at diagnosis.
For overall survival cytogenetics was also the most important independent prognostic factor. In addition, several other factors had prognostic value. Increasing age was negatively associated with survival. A normal white blood cell count and a platelet count between 50 and 100 × 10 9 /l predicted independently for a better survival and patients with a hemoglobin of at least 10 g/dl at the start of therapy also showed a better survival. Recently, various scoring systems for the prognosis of MDS patients were developed. 1, [24] [25] [26] [27] [28] [29] Several authors stressed the importance of a normal WBC and hemoglobin of at least 10 g/dl. [24] [25] [26] Morel et al 27, 28 included cytogenetics in their scoring system. In 1997 Greenberg et al 1 used the data of previously reported studies to generate an international prognostic scoring system (IPSS). They distinguished four risk Leukemia groups based on cytogenetics, number of cytopenias and bone marrow blasts. However, the majority (75%) of patients in the IPSS study was older than 60 years and these patients have been treated with supportive care only or low intensity regimens.
Our principal findings are that a strategy offering allografting in CR, or autografting if a compatible donor was unavailable appeared to produce longer disease-free survival, but similar survival than chemotherapy alone. Survival from start of treatment considering all 399 patients was not significantly influenced by the two different treatment strategies. These findings are thus reminiscent of those found when emphasis has been placed on patients with de novo AML.
Several points must be stressed. First and perhaps most important, the value of chemotherapy vs transplantation as post-remission treatment was raised neither prospectively nor in the context of a randomized clinical trial. The EORTC study included high-risk MDS patients only and for the present analysis successive MDA patients were retrospectively selected on the basis of the EORTC eligibility criteria. The EORTC cohort included eight RA(RS) patients with multiple chromosome abnormalities and/or profound cytopenias and 16 CMMoL patients with bad prognostic features. Since MDA used protocols not calling for AML-like therapy to treat CMMoL, MDA patients with CMMoL were not included in the study group. RA (RS) patients with bad prognostic features neither were treated according to these protocols in MDA. At the time of initiating the present analysis the new WHO classification was not yet issued. 30 This classification considers CMMoL as a myelodysplasic/myeloproliferative disease rather than a myelodysplastic syndrome. However, when we excluded the CMMoL patients from the EORTC cohort the overall results of the EORTC and the comparison with the MDA remained practically unchanged. The overall survival rate at 4 years of the EORTC cohort including the CMMoL patients was 26.0% compared to 25.9% by excluding them. The prognostic importance of the other factors did not change drastically. Excluding the CMMoL patients would further increase the imbalance of the WBC distribution. Similarly, the DFS rate at 4 years was 28.9% including the CMMoL patients compared to 28.8% by excluding them. Finally, the survival rate from CR was 34.4% including CMMoL patients and 34.7% by excluding them (data not shown). So our results remained unchanged, if we had excluded the CMMoL patients.
Secondly, although the multivariate regressions may have accounted for differences in the distribution of known covariates (eg age) between the MDA and EORTC cohorts, it is very difficult to ascertain whether these cohorts differed with regard to potentially important but unknown covariates. For example, it is impossible to ascertain whether the proportion of patients who were eligible for the studies described here but were not entered was similar in the EORTC and at MDA.
A third difficulty is that we consider 'transplantation' as one strategy regardless of whether patients received an allograft or an autograft and we have also assumed that results were equivalent at all EORTC centers contributing data to this analysis. Similarly, we have assumed that the various MDA chemotherapy regimens were approximately identical. A fourth difficulty is that the EORTC and MDA induction regimens differed, with the latter employing higher doses of ara-C. Several reports have noted that the therapy given during induction can influence outcome in CR. 31 For example, it can be argued that the higher CR rate produced by the MDA induction regimens, with these higher rates reflecting a lower 'resistance' rate, would tend to make the MDA post-remission treatment strategy appear better a priori. It could also be contended, however, that because the MDA induction regimens produced CRs in patients who would not have achieved CR with the 'ICE' regimen, the MDA post-remission strategy would appear inferior a priori given that the MDA patients were more likely to relapse perhaps due to factors that cannot currently be specified ('latent variables').
A final difficulty is that obviously we cannot speak about the strategy of transplantation at diagnosis rather than in CR. Several of these difficulties will be addressed in the ongoing prospective randomized European study (EORTC 06961) comparing high-dose cytarabine with peripheral blood stem cell transplantation as post-consolidation treatment after a common remission-induction and consolidation course.
Pending results of this trial, it appears that our results lend support to either strategy. Supporters of a transplant strategy can claim that this strategy appears to unequivocally lengthen disease-free survival in CR. Supporters of a chemotherapy strategy can point to the absence of a major effect of transplantation on survival. Perhaps then the important question may not be which strategy is superior, but rather whether either can be made to produce better results.
